|Bid||3.9400 x 1100|
|Ask||4.4400 x 1100|
|Day's Range||4.2000 - 4.6000|
|52 Week Range||3.2620 - 8.9400|
|Beta (5Y Monthly)||1.69|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.33|
In addition to causing chaos in markets and economies around the world, the spread of the COVID-19 coronavirus has put the biotechnology and health care industries under the microscope.Suddenly, hundreds of such companies are redirecting resources in an effort to find a vaccine or treatment that could potentially halt the virus' spread. This has made the biotech space one of the few hot spots in a historically bad month for stocks.The shelter-in-place orders in the U.S. and other countries have also made it difficult for many of these companies to communicate directly with investors. This is especially challenging for biotech companies, which are often more communicative with investors than companies in other industries. Expensive drug trial and capital raising cycles, make constant communication with investors essential, according to John Viglotti, senior vice president of corporate services and investor access at OTC Markets."They are faced with a constant need to raise capital to fund clinical trials, and these clinical trials are not stopping," he said. "The life science business is certainly continuing."In an effort to bridge that gap between investors hungry for information and companies trying to reach them, OTC Markets is hosting the first Virtual Life Science Investor Forum on March 26. The online-only conference will consist of investor presentations from seven companies in five countries. Some will be giving updates on their COVID-19 treatments."Certainly with what's going on with the coronavirus pandemic, it just makes it that much more relevant," said Jason Paltrowitz, executive vice president of corporate services at OTC Markets. "The public at large is certainly interested in COVID-19, but from an investor perspective there are great opportunities."According to Viglotti, over 200 life sciences companies have previously participated in virtual investor conferences, making it one of the most popular sectors to participate in the conference series."It was really done with the realization that there are so many pre-revenue, early stage private life science companies that are just starved for attention," Paltrowitz said of this week's conference. "And we thought being able to host a series of virtual conferences would help."Below is the schedule for the conference. Each presentation is followed by a virtual Q&A session with attendees and is available on demand.To learn more about attending Thursday's conference, click here.9:30 AM ET RedHill Biopharma Ltd. (NASDAQ: RDHL) Speaker: Guy Goldberg, Chief Business Officer About: RedHill is a specialty biopharmaceutical company focused on gastrointestinal diseases. RedHill has commercial operations in the U.S., with a sales force promoting several gastrointestinal drugs across the U.S., including RedHill's recently FDA approved drug, Talicia®. RedHill also has a robust development pipeline with several late-stage development programs which have successfully completed Phase 3 studies.10:00 AM ET Nuvo Pharmaceuticals Inc. (OTCQX: NRIFF) Speakers: Jesse Ledger, President & Chief Executive Officer, and Kelly Demerino, Interim Chief Financial Officer About: Nuvo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy and dermatology. The Company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.10:30 AM ET Orexo AB (OTCQX: ORXOY) Speaker: Nikolaj Sørensen, President & CEO About: Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs mainly within the growing space of addiction. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product Zubsolv® for treatment of opioid use disorder.11:00 AM ET Emmaus Life Sciences, Inc. (OTCQB: EMMA) Speakers: Dr. Yutaka Niihara, Chairman and Chief Executive Officer, and Jay Sherwood Chief Financial OfficerAbout: Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. Its FDA-approved Endari® (prescription grade L-glutamine oral powder) is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.11:30 AM ET Moleculin Biotech, Inc. (NASDAQ: MBRX) Speaker: Walter Klemp, Founder, President, CEO & Chairman About: Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as compounds capable of Metabolism/Glycosylation Inhibition.12:00 PM ET Lexaria Bioscience Corp. (OTCQX: LXRP) Speaker: Chris Bunka, CEO About: Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its patented DehydraTECH™ drug delivery technology changes the way API's enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and can reduce drug costs for orally administered bioactive molecules including nicotine, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and other molecules. Lexaria has licensed DehydraTECH to multiple companies for use in various oral application formats, including to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.12:30 PM ET Beroni Group Ltd. (OTCQX: BNIGF) Speakers: Jacky Zhang, Chairman and CEO, and Peter Wong, Group CFO About: Beroni Group is an international biotechnological company listed on the National Stock Exchange (Australia) with business presence in Australia, China, Japan and the USA. It currently has four core businesses - cell therapies, developing new anti-cancer drugs, e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases.To learn more about attending Thursday's conference, click here.Photo by ThisisEngineering RAEng on UnsplashSee more from Benzinga * There's A New Tool That Helps Investors Understand The Corporate Structure Of US Banks * 10 International ADR Companies That Are Conducting Virtual Investor Presentations This Week * Despite Volatility, FANG Continues to Prove Its Popularity(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
“Our primary objective during this global pandemic is to safeguard the health of our employees, healthcare workers, families and communities while minimizing the impact on our commercial and R&D operations,” said Dror Ben-Asher, Chief Executive Officer of RedHill Biopharma. The initiation of the pivotal Phase 3 study evaluating RHB-204 as a first-line, stand-alone treatment for pulmonary nontuberculous mycobacteria (NTM) infections caused by Mycobacterium avium complex (MAC) is planned to be deferred by one quarter, to the third quarter of 2020.
NEW YORK, March 24, 2020 -- Life Sciences Investor Forum today announced the agenda for its inaugural event for public and private companies, investors and industry.
This will be a live, online presentation where the audience is invited to ask the Company questions in real-time. The live broadcast and Q&A session can be accessed via the Company's website, http://ir.redhillbio.com/events. A replay of the presentation will be available for 30 days via the Company’s website: http://ir.redhillbio.com/events.
RedHill recently launched Talicia® in the U.S., calling on gastroenterologists, primary care physicians and other healthcare providers --- Talicia® is the first and.
Phase 2 study evaluating RedHill’s proprietary NCE1 opaganib (Yeliva®, ABC294640) in prostate cancer initiated at Medical University of South Carolina, supported by an NCI.
The presentation will be broadcast live and available via replay for 30 days on the Company's website, http://ir.redhillbio.com/events. RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases.
Talicia® is the first and only FDA-approved rifabutin-based therapy for treatment of H. pylori infection designed as a first-line option to address the high and growing H..
Actinium (ATNM) treats first patient in the third and final cohort of the Actimab-A and CLAG-M combination phase I study to treat relapsed or refractory acute myeloid leukemia.
Key Highlights: Talicia® approved by the FDA for the treatment of H. pylori infection in adults; U.S. launch with RedHill’s sales force expected by mid-March 2020 Acquisition.
The Company will host a conference call on Wednesday, March 4, 2020, at 8:30 a.m. EST to review the financial results and operational highlights. The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, http://ir.redhillbio.com/events.
RedHill to promote Movantik® in the U.S. upon closing Movantik® generated U.S. net sales of $96 million in 2019Acquisition financing to be provided by HealthCare Royalty.
RedHill to receive $30 million following closing to support its commercial operations, including the planned launch of Talicia® this quarter and the ongoing promotion of.
The presentation will be broadcast live and available via replay for 30 days on the Company's website, http://ir.redhillbio.com/events. RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company, primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases.
RedHill is on track to launch Talicia® in the U.S. in the first quarter of 2020 for the treatment of H. pylori infection in adults- - - RedHill to sponsor H. pylori medical.
RedHill Biopharma will end its commercialization agreements with Entera Health and Advanz Pharma Corp.
RedHill provided a notice of termination to Entera Health regarding the license agreement for EnteraGam® and the co-promotion agreement with Advanz Pharma Corp. for Donnatal® will not be renewed. RedHill has been promoting Donnatal® and EnteraGam® since mid-2017. “Prioritizing our commercial efforts allows us to focus on our most valuable products, Talicia® and Aemcolo®, as well as giving us capacity to bring on other important products, which are currently under discussion,” said Dror Ben-Asher, RedHill’s Chief Executive Officer.
“We are pleased to regain the rights to RHB-106, which aligns well with our expanded gastrointestinal-focused commercial activities in the U.S., and to pursue its development toward potential U.S. FDA approval,” said Dror Ben-Asher, RedHill’s CEO.
Aemcolo® (rifamycin) is a non-systemic antibiotic delivered directly to the site of non-invasive E. coli infection in the lower intestineAemcolo® is approved by the FDA for the.
Zacks Market Edge Highlights: Boot Barn, Alteryx, RedHill Biopharma, Innovative Industrial Properties and SPS Commerce
Key Highlights: U.S. FDA approval of Talicia® for the treatment of Helicobacter pylori infection in adults Strategic partnership with Cosmo Pharmaceuticals, including.